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Abstract
Introduction
Inappropriate DNA methylation is frequently associated with human tumour development,
and in specific cases, is associated with clinical outcomes. Previous reports of DNA
methylation in low/intermediate grade non-muscle invasive bladder cancer (NMIBC) have
suggested that specific patterns of DNA methylation may have a role as diagnostic or prog-
nostic biomarkers. In view of the aggressive and clinically unpredictable nature of high-
grade (HG) NMIBC, and the current shortage of the preferred treatment option (Bacillus:
Calmette-Guerin), novel methylation analyses may similarly reveal biomarkers of disease
outcome that could risk-stratify patients and guide clinical management at initial diagnosis.
Methods
Promoter-associated CpG island methylation was determined in primary tumour tissue of
36 initial presentation high-grade NMIBCs, 12 low/intermediate-grade NMIBCs and 3 nor-
mal bladder controls. The genes HOXA9, ISL1, NKX6-2, SPAG6, ZIC1 and ZNF154 were
selected for investigation on the basis of previous reports and/or prognostic utility in low/
intermediate-grade NMIBC. Methylation was determined by Pyrosequencing of sodium-
bisulphite converted DNA, and then correlated with gene expression using RT-qPCR. Meth-
ylation was additionally correlated with tumour behaviour, including tumour recurrence and
progression to muscle invasive bladder cancer or metastases.
Results
The ISL1 genes’ promoter-associated island was more frequently methylated in recurrent
and progressive high-grade tumours than their non-recurrent counterparts (60.0% vs. 18.2%,
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p = 0.008). ISL1 andHOXA9 showed significantly higher meanmethylation in recurrent and
progressive tumours compared to non-recurrent tumours (43.3% vs. 20.9%, p = 0.016 and
34.5% vs 17.6%, p = 0.017, respectively). Concurrent ISL1/HOXA9methylation in HG-
NMIBC reliably predicted tumour recurrence and progression within one year (Positive Pre-
dictive Value 91.7%), and was associated with disease-specific mortality (DSM).
Conclusions
In this study we report methylation differences and similarities between clinical sub-types of
high-grade NMIBC. We report the potential ability of methylation biomarkers, at initial diag-
nosis, to predict tumour recurrence and progression within one year of diagnosis. We found
that specific biomarkers reliably predict disease outcome and therefore may help guide
patient treatment despite the unpredictable clinical course and heterogeneity of high-grade
NMIBC. Further investigation is required, including validation in a larger patient cohort, to
confirm the clinical utility of methylation biomarkers in high-grade NMIBC.
Introduction
High-grade non-muscle invasive bladder cancer (HG-NMIBC) is a clinically important sub-
type of bladder transitional cell carcinoma (TCC), accounting for 10–15% of all TCC at presen-
tation[1].The unpredictable nature of HG-NMIBC with regard to recurrence and progression
to invasive or metastatic disease, presents many challenges for successful management. With
no robust methods for predicting outcomes (recurrence, progression, Bacillus:Calmette-Guerin
(BCG) failure) at initial diagnosis, patients may be under-treated with intravesical therapy
alone or over-treated with immediate cystectomy, both with attributed adverse patient out-
comes[2,3].
Multiple studies have described the importance of epigenetic modifications in tumourigen-
esis, most frequently apparent as inappropriate DNAmethylation within gene promoter-
associated CpG islands, and/or changes that lead to histone tail modification(s)[4,5].These
modifications impact upon gene expression and promote tumourigenesis predominantly by
silencing of tumour-suppressor and/or apoptotic pathway genes[5,6]. Such epigenetically-
mediated gene silencing has been demonstrated in NMIBC and muscle-invasive bladder cancer
(MIBC), and is reported to be associated with tumour recurrence, progression, invasion, and
metastasis, but also early events in tumour development such as the ‘field-defect’ phenomenon
[7,8]. Recent studies highlight the potential clinical utility of epigenetic biomarkers in bladder
cancer, describing tumour, blood and urine DNA methylation markers of, for example,
NMIBC recurrence or chemo-resistance in MIBC[9–11].
Promoter-associated CpG Island methylation of theHOXA9, ISL1, NKX6-2, SPAG6, ZIC1
and ZNF154 genes are frequent findings in bladder cancer. In these cases, methylation appears
associated with aggressive tumour characteristics, and may independently predict disease
recurrence, progression, or disease-specific mortality (DSM)[9,12,13]. However the majority of
these reports examine heterogeneous cohorts, comprising predominantly low/intermediate-
grade NMIBC; high-grade NMIBC has not been considered discretely for disease and/or sub-
type specific epigenetic modifications.
We assessed a unique cohort of patients with HG-NMIBC for inappropriate promoter-asso-
ciated CpG Island methylation at initial presentation and removal of the primary tumour(s),
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with respect to known prospectively collected one-year outcomes of no-recurrence, recurrence,
and progression (to MIBC or metastatic disease), and relative to low/intermediate-grade
NMIBC. Identifying inappropriate methylation ‘at diagnosis’ of HG-NMIBC permitted a pre-
liminary identification of novel and potentially clinically useful prognostic biomarkers.
Materials and Methods
Human tissue samples
The primary tumour and normal bladder tissues used were provided by the Bladder Cancer
Prognosis Programme (BCPP, Nottingham Research Ethics Committee: 05/Q2404/173)[14],
the University of Birmingham Human Biomaterials Resource Centre (National Research Ethics
Service (North West 5): 09/H1010/75), and the University Hospitals of North Midlands NHS
Trust (National Research Ethics Service (South Central–Oxford C): 12/SC/0725). All samples
were obtained after informed written consent and under the approval of appropriate national
ethics review boards (reference numbers stated above). All samples were confirmed histologi-
cally; repeat trans-urethral resection or cystectomy were performed, and/or intravesical ther-
apy provided, where suggested by European Association of Urology Guidelines [15]. All
primary human tissues (Table 1) were stored at -80°C prior to nucleic acid extraction.
DNA extraction and bisulphite modification
Genomic DNA was extracted from tumour and control tissues using a standard phenol-chloro-
form extraction procedure[16] and subsequently bisulphite-modified as previously described
[4]. Bisulphite conversion of DNA was confirmed in all cases by successful PCR using primers
specific to bisulphite-converted DNA (primer sequences provided in supporting information
S1 Table). To increase the relative amount and stability of bisulphite-converted DNA, whole-
Table 1. Patient and Tumour characteristics.
Cohort Number Age Grade Stage Follow-
up
Time to
recurrence
Time to
progression
Time to disease-speciﬁc
mortality
(years) (G1/G2/
G3)
(Ta/
T1)
(months) (months) (months) (months)
Controls 3 68 (67–
74)
Low/intermediate-grade
Cohort
12 69 (47–
82)
3/9/0 5/7 8 (4–11) A n/a n/a
High-grade Cohort 36 75 (45–
92)
18 (7–68)
No-recurrence 11 75 (59–
84)
59 (12–
67)
n/a n/a B
Recurrence 11 84 (67–
92)
31 (12–
67)
5 (2–7) C 16 (15–54)
Progression 14 73 (45–
84)
11 (7–33) n/a 8 (2–10) 9 (1–21)
Number of samples in each cohort, with median age, range in brackets, and median follow-up period, range in brackets, after initial tumour resection
(diagnosis).
AOne patient suffered a 2mm uni-focal recurrence at 6 months.
BOne patient in the no-recurrence group suffered disease speciﬁc mortality at 16 months.
COne patient in the recurrence one-year group suffered progression at 21 months.
doi:10.1371/journal.pone.0137003.t001
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genome amplification (WGA) was performed as previously described[4] (described further in
supporting information S1 Text).
Pyrosequencing of bisulphite-converted DNA
CpG island sequences were identified from the UCSC Genome Browser (http://genome.ucsc.
edu/), and imported into PyroMark Assay Design 2.0 Software for primer design (Qiagen,
Manchester, UK). Dependent on the frequency and density of CpG dinucleotides within the
sequence of interest, designed primers encompassed 4–7 consecutive CpGs in each gene
(primer sequences in S1 Table and details of genomic location in S2 Table). After PCR amplifi-
cation of the target sequence, Pyrosequencing was performed using a PyroMark Q24 Pyrose-
quencer using PyroMark Q24 Software 2.0 and PyroMark Gold Q24 Reagents (Qiagen), as
previously described [17] (S1 Text).
Methylation was stringently defined in tumours as comprising a mean level of methylation
across the CpGs surveyed of greater than four standard deviations (4SD) above the mean in
normal controls [4]. The number of tumours methylated (by this definition) for any given gene
describes the frequency of methylation, whereas the mean percentage methylation of all CpGs
surveyed describes themean level of methylation for a tumour in any particular gene.
Quantitative RT-PCR
Total RNA was extracted from control and tumour samples using a standard guanidinium
thiocyanate-phenol-chloroform protocol[16], and complementary DNA synthesised as described
previously[18].Thermal cycling using SYBR (III) Green was as previously described [19], with
target genes normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (S1 Table) as
endogenous control (S1 Text). Relative quantification of transcript expression was performed
using the 2-ΔΔ cycle threshold (CT) method[20]. Reduced transcript expression in each tumour
was regarded significant if lower than a 3-fold reduction relative to mean expression in control
samples; the converse was true for increased transcript expression [18](S1 Text).
Informatics and statistics
Microsoft Excel 2010 and STATA (v8, Stata Corporation, TX) were used to perform Fisher’s
exact, Students’ t, and log-rank analyses, and sensitivity, specificity, and positive and negative
predictive values of methylation with respect to clinical outcomes.
Results
Frequency of methylation within low/intermediate- and high-grade
NMIBC
We initially determined the methylation status of the six candidate genes in the high- and low/
intermediate-grade tumour cohorts by Pyrosequence analyses of bisulphite-converted DNA.
Inappropriate methylation of promoter-associated CpG islands (S2 Table) was a frequent find-
ing in both cohorts for the NKX6-2, SPAG6, ZIC1 and ZNF154 genes, relative to normal blad-
der (Table 2).
Table 2 shows that the methylation frequency in low/intermediate-grade tumours was
lower for ISL1 than for all other genes investigated (2/12 tumours; 16.7%), although by com-
parison, methylation frequency increased within HG tumours (17/36; 45.0%, p = 0.091). Con-
versely, frequency of methylation was lower in HG-NMIBCs for HOXA9 (20/36; 55.6%)
compared to low/intermediate-grade tumours (10/12; 83.3%, p = 0.167); (data summarised in
Table 2).
Methylation Predicts Bladder Cancer Outcome
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To further investigate potential reasons for the observed differences in the frequency of
methylation between the high- and low/intermediate-grade tumour cohorts for specific genes,
we determined gene-specific methylation frequencies relative to the clinical characteristics of
the HG tumours, encompassing one-year clinical outcomes of no-recurrence, recurrence, and
progression.
For NKX6-2, SPAG6, ZIC1 and ZNF154, methylation frequencies in recurrence and progres-
sion tumours were marginally greater than their no-recurrence counterparts, and were overall
broadly similar to the frequencies apparent in low/intermediate-grade tumours (Fig 1).
HOXA9 demonstrated a similarly increased methylation frequency in recurrence and pro-
gression tumours relative to their no-recurrence counterparts, however, as shown in Fig 1, the
methylation frequency in no-recurrence tumours was significantly lower compared to that
observed in low/intermediate-grade tumours (p = 0.036). Although the trend of an increase in
methylation frequency in recurrence and progression (relative to no-recurrence) tumours was
Table 2. Methylation frequency andmean level of methylation in low/intermediate- and high-grade tumour groups.
Methylation Frequency Mean Level of Methylation
Low/intermediate-grade High-grade Normal bladder control Low/intermediate-grade High-grade
Gene name Number (%) Number (%) p value (%) (%) (%) p value
HOXA9 10/12 (83.3) 20/36 (55.6) 0.167 6.1 44.0 29.3 0.057
ISL1 2/12 (16.7) 17/36 (47.2) 0.091 7.6 22.1 38.9 0.061
NKX6-2 10/12 (83.3) 32/36 (88.9) 0.631 5.4 38.9 50.2 0.126
SPAG6 10/12 (83.3) 32/36 (88.9) 0.631 8.2 38.5 52.1 0.097
ZIC1 11/12 (91.7) 31/36 (86.1) 0.999 17.3 62.2 58.6 0.545
ZNF154 10/12 (83.3) 32/36 (88.9) 0.631 7.6 44.1 53.1 0.318
Number and percentage of low/intermediate- and high-grade tumours that are methylated for each of the six candidate genes (left side of table) and the
mean level of methylation in each cohort for each of the gene (right side of table). Methylation is deﬁned using four standard deviations above the mean of
the normal bladder controls as a cut-off, as described previously[4]. Differences in the number of tumours methylated comparing high- to low/intermediate-
grade tumours were assessed using Fisher’s exact or Chi-squared tests (two-tailed), where p<0.05 is considered signiﬁcant. Differences in mean
methylation were assessed by Students t test, p<0.05 again considered signiﬁcant.
doi:10.1371/journal.pone.0137003.t002
Fig 1. Proportion of methylated tumours in low/intermediate- and high-grade tumour cohorts. From
left to right, tumour cohort methylation frequency/proportion, as determined by Pyrosequencing within
HOXA9, ISL1, SPAG6, NKX6-2, ZIC1 and ZNF154, for the low/Intermediate-grade cohort (LG), no-recurrence
(NR) and recurrence and progression tumours (R+P) respectively. The filled bars represent the proportion of
methylated tumours relative to controls in each case. Differences between the frequencies of methylation are
indicated as statistically significant by ‘*’, where p<0.05 as determined by Fisher’s exact or Chi-squared tests
(two-tailed). Methylation was defined as described in the materials and methods.
doi:10.1371/journal.pone.0137003.g001
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apparent for all genes investigated, this was distinctly more marked for the ISL1 gene. In this
case, methylation frequency was significantly greater in recurrence and progression tumours
relative to no-recurrence (15/25 (60.0%) vs 2/11 (18.2%), p = 0.031), and also to their low/inter-
mediate-grade counterparts (15/25 (60.0%) vs 2/12 (16.7%), p = 0.017) (Fig 1).
Mean methylation levels within low/intermediate- and high-grade NMIBC
Our methylation analyses also showed considerable differences in, and between, the mean and
range of methylation levels within individual tumours (Fig 2). Therefore, in addition to the
analyses described above, we also assessed mean methylation levels within HG and low/inter-
mediate-grade cohorts and within the HG tumour sub-types, to determine whether the level of
methylation demonstrated any relationship with clinical characteristics.
The mean level of methylation was greater, albeit not significantly, in HG relative to their
low/intermediate-grade counterparts for the ISL1, SPAG6,NKX6-2, and ZNF154 genes
(Table 2). This increase approached significance for ISL1 (22.1% vs 36.5%, p = 0.061). Paradoxi-
cally, the mean level of methylation forHOXA9was lower in HG compared to their low/interme-
diate-grade counterparts, again approaching significance (29.3%vs 44.0%, p = 0.057) (Table 2).
Fig 2. Level of methylation within low/intermediate- and high-grade tumour cohorts. Panels (a) to (f)
representingHOXA9, ISL1, NKX6-2, SPAG6, ZIC1 and ZNF154, respectively. Each panel displays individual
tumour methylation values, as determined by Pyrosequencing, represented by grey circles within control (c),
low/Intermediate-grade (LG), no-recurrence (NR) and recurrence and progression (R+P) tumour groups. The
solid horizontal bars represent the overall mean methylation within each control or tumour group; differences
between the means are indicated as statistically significant by ‘*’, where p<0.05 determined by Students-t
testing. The double-headed arrow represents the cut-off point above which tumours are defined as
methylated relative to normal bladder controls.
doi:10.1371/journal.pone.0137003.g002
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Using this approach, we also determined gene-specific methylation levels within HG
tumours and relative to their clinical outcomes. Mean methylation levels within ISL1 and
HOXA9 were significantly higher in recurrence and progression tumours compared to their
no-recurrence counterparts (43.3% vs. 20.9%, p = 0.016 and 34.5% vs. 17.6%, p = 0.017, respec-
tively) (Fig 2). The mean methylation level increase from no-recurrence to recurrence and pro-
gression tumours was not significant for NKX6-2, SPAG6, ZIC1 and ZNF154.
Correlation of methylation within clinical outcomes of high-grade NMIBC
We next determined the correlation between gene-specific methylation with clinical outcomes
within the HG tumour cohort;HOXA9 and ISL1 were assessed as the only genes demonstrating
a significant difference in frequency or level of methylation.HOXA9 promoter methylation
demonstrated 72.7% specificity and an 84.2% positive predictive value (PPV) for tumour recur-
rence and/or progression within one year of initial diagnosis, whilst methylation within the
ISL1 promoter demonstrated specificity of 81.8% and PPV 87.5% for the same clinical out-
comes, shown in Table 3. Moreover, concomitant methylation ofHOXA9 and ISL1 at initial
diagnosis predicted one-year recurrence and/or progression, with a PPV of 91.7%, whilst main-
taining a specificity of 90.9%. To more rigorously assess association between these potential
biomarkers and disease outcome, we employed logistical regression analysis. Table 3 shows
that when considered individually, methylation of either HOXA9 or ISL1 attained statistical
significance with tumour recurrence and/or progression (p = 0.050 and p = 0.047 respectively).
However, in combination, while the biomarkers were less significantly associated with disease
outcome (p = 0.067), they demonstrated a stronger odds ratio of tumour recurrence and/or
progression than when either was considered separately (7.86 vs 4.74 and 5.73, respectively).
In addition to tumour behaviour we also considered promoter methylation as a predictor of
disease-specific mortality: In this case, HOXA9 promoter methylation demonstrated 57.1%
specificity and a 70.6% negative predictive value (NPV) for disease-specific mortality, whilst
ISL1methylation suggested 57.1% and 60.0% for these outcome measures.
Methylation-associated changes in gene expression in high-grade
NMIBC
Quantitative RT-PCR was used to evaluate associations between methylation and gene expres-
sion in four of the six genes within a sub-set of 10–14 tumours, in comparison to controls. Fig
3 shows that, relative to controls, 90.1% (29 of 32) methylated tumours display reduced tran-
script expression, and 75.0% (24 of 32) show significantly reduced expression. Conversely,
Table 3. Methylation biomarker utility in high-grade NMIBC.
Outcome Potential Biomarker Odds Ratio 95% Conﬁdence Interval p value
HOXA9 4.7 1.0–22.5 0.05
Recurrence or Progression ISL1 5.7 2.1–32.1 0.047
HOXA9 + ISL1 7.9 0.9–71.1 0.067
Outcome Potential Biomarker Sensitivity Speciﬁcity Positive Predictive Value Negative Predictive Value
HOXA9 64.00% 72.70% 84.20% 47.10%
Recurrence or Progression ISL1 56.00% 81.80% 87.50% 45.00%
HOXA9 + ISL1 44.00% 90.90% 91.70% 41.70%
Values for sensitivity, speciﬁcity, positive predictive value, negative predictive value, odds ratio (with 95%CI) and p-value of potential methylation
biomarkers HOXA9 and ISL1 individually, and in combination, to predict high-grade NMIBC recurrence or progression at one year after initial diagnosis.
doi:10.1371/journal.pone.0137003.t003
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56.3% (9 of 16) unmethylated tumours displayed expression levels similar to, or in some cases
higher than, that apparent in controls.
Discussion
The epigenomic landscape of bladder cancer is an area of growing research interest[21], specifi-
cally in relation to identifying clinically viable biomarkers. Due to the current limitations in
predicting the diverse clinical outcomes observed in HG-NMIBC, and the present BCG short-
age, biomarkers that guide clinical decisions are of particular importance[22,23]. As described
above, our analyses revealed frequent, and in some cases differential methylation, present at
initial HG-NMIBC diagnosis, that appeared to correlate with tumour characteristics and clini-
cal parameters.
The six genes selected for analyses are predominantly members of transcription factor fami-
lies, primarily regulating gene-expression, enzyme-binding, and cell differentiation[24]. Their
selection for analyses was on the basis of their frequent inappropriate methylation in bladder
cancer [9,12,13,25]. In previous reports, HOXA9 and ZNF154methylation has been associated
with tumour recurrence, and ISL1methylation with tumour progression in predominantly
low/intermediate-grade tumours[9,13].
Our initial analyses revealed similar methylation frequencies in low/intermediate- and
HG-NMIBC for NKX6-2, SPAG6, ZIC1 and ZNF154. In these cases, methylation frequencies
were similar to those previously reported in the literature[9,12,13,25]. However, a difference in
the frequency of methylation was apparent between the low/intermediate- and HG-NMIBC
cohorts for HOXA9 and ISL1 genes: although the methylation frequency of the HOXA9 pro-
moter in low/intermediate-grade tumours was similar to that previously described in the litera-
ture [12,13], it was found at markedly lower frequency in HG-NMIBC. Conversely, for ISL1,
methylation frequency in low/intermediate-grade tumours was lower than described previ-
ously by others[13]; however, the methylation frequency increase that is apparent in the recur-
rence and progression tumours is more consistent with these reports.
Fig 3. Association between high-grade NMIBC tumour methylation and gene expression.Quantitative
RT-PCR analyses of HOXA9, ISL1, SPAG6 and ZNF154 transcript expression in individual high-grade
tumours (HG). Expression is reported relative to the mean of three normal bladder controls (C, triangles),
where the mean value is expressed as equal to 100%. Filled and unfilled circles denote methylated or
unmethylated tumours, and represent the mean value from two independent experiments performed in
triplicate. The horizontal bars within the control column represent the mean of the controls, a 3-fold reduction
beneath this lies the double-headed arrow in each gene plot, representing the cut-off for significantly reduced
expression in tumours relative to controls.
doi:10.1371/journal.pone.0137003.g003
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The differential methylation frequency in HOXA9 and ISL1may relate to several confound-
ers, including the method in this study employed to define tumour methylation, and the rela-
tively few low/intermediate-grade tumours for analyses. However, the concordance between
our methylation data and those reported by others for NKX6-2, SPAG6, ZIC1 and ZNF154,
confirms the robustness of our approach. On this basis, we reasoned that the differences in
methylation frequency observed for HOXA9 and ISL1may be consequent to different clinical
characteristics and/or outcomes within our HG tumour cohort; a phenomenon similarly
described in, for example, breast, colon and pituitary tumours[4,26,27]. We therefore per-
formed HG-NMIBC sub-type analyses and found that the methylation profiles of recurrence
and progression tumours, although similar to each other, were mostly quite distinct from their
no-recurrence counterparts; on this basis we grouped recurrence and progression tumours for
analyses.
The methylation frequency in recurrence and progression tumours was consistently higher
across all six genes compared to their no-recurrence counterparts; these differences were most
pronounced for HOXA9 and ISL1 and achieved statistical significance for ISL1. Paradoxically,
inHOXA9, no-recurrence, recurrence and progression tumours were less frequently methyl-
ated than in their low/intermediate-grade tumour counterparts. Although the reasons for this
are unclear, possible explanations may relate to the number, or heterogeneity, of tumours
investigated, though we cannot discount the possibility that there are epigenetic differences in
particular genes between low/intermediate- and high-grade tumours. Conversely, methylation
frequency in recurrence and progression tumours in ISL1 was markedly greater than in their
low/intermediate-grade counterparts. Similar explanations to those described for HOXA9
might account for these observations.
Through quantitative Pyrosequence analyses, we determined mean methylation across mul-
tiple CpG sites showing that, further to methylation frequency differences, there exist differ-
ences in methylation levels between tumour cohorts for particular genes. Specifically,
differences in mean methylation levels between low/intermediate- and HG tumours, and also
between the no-recurrence, and their recurrence and progression tumour counterparts, analo-
gous to observations reported by others in breast and colon cancer sub-types[26,27]. For both
HOXA9 and ISL1, there was a significant increase in the mean level of methylation in the recur-
rence and progression tumours compared to their no-recurrence counterparts.
The observed differences in methylation frequency and mean methylation level between
these clinically divergent subgroups, suggests that the frequency and/or mean level of methyla-
tion increases with tumour aggressiveness. Similar trends have been reported in other tumour
types[26,27] and this is thought to represent accumulation of epigenetic aberrations over time,
similar to the accumulation of genetic mutations and genomic instability apparent during
tumour progression[28].
Since our findings support previous associations ofHOXA9 and ISL1methylation with
tumour characteristics and behaviour[9,13], we appraised potential clinical correlates of
HOXA9 and ISL1methylation, including their prognostic potential. In our HG-NMIBC
cohort, HOXA9 or ISL1methylation at initial diagnosis reliably predicted tumour recurrence
or progression within one year. In this context, concurrent methylation of bothHOXA9 and
ISL1 improved the positive predictive value to 91.7%, comparing favourably with other postu-
lated biomarkers of recurrent/progressive disease in NMIBC [13,29]. Moreover, logistic regres-
sion appeared to confirm that these findings were not consequent to methylation in a single
gene. Furthermore, and as previously described[9,13], concurrent methylation inHOXA9 and
ISL1 was associated with DSM and reduced overall survival, however, this did not reach
statistical significance. In this context, we recognise that the number of tumours available for
investigation and in the absence of similar reports, that the associations we report between
Methylation Predicts Bladder Cancer Outcome
PLOSONE | DOI:10.1371/journal.pone.0137003 September 2, 2015 9 / 12
inappropriate methylation and HG-NMIBC disease outcome will require validation in larger,
independent tumour cohorts.
Finally, to reveal potential functional relevance of methylation within high-grade disease,
we assessed the relationship between methylation and gene expression; across the four genes
studied, we found an association of abnormal methylation with reduced transcript expression,
consistent with findings from other groups[9,13]. These findings were not significant, possibly
relating to number of tumours studied, or the passenger/driver phenomenon, whereby epige-
netic marks may be present but not causative of altered gene expression[30].
These findings are the first to report similarities and differences of gene-associated methyla-
tion in HG-NMIBC relative to low/intermediate-grade tumours. Furthermore, we have shown
that specific methylation patterns at initial diagnosis predict one-year HG-NMIBC clinical out-
comes, pointing to the exciting potential for methylation as a prognostic biomarker in this clin-
ically unpredictable disease. Further investigations exploiting genome-wide array analyses are
required to further characterise epigenetic similarities and differences between low/intermedi-
ate-and HG-NMIBC, and to reveal biomarkers that may serve as therapeutic targets or guide
clinical management, such as the timing, dose and length of BCG therapy, or timing of
cystectomy.
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